0211 AC Immune
BioCentury & Getty Images

Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s 

Feb 12, 2021 | 1:45 AM GMT

AC Immune believes it has hit on a breakthrough in vaccine technology with its Alzheimer’s candidate ACI-35. The rest of the world will have to wait to evaluate the claim, as the company and partner Janssen aren’t ready to disclose the data.

The biotech announced interim results Thursday from a Phase Ib/IIa trial of the anti-tau vaccine, stating that 100%

Read the full 802 word article

How to gain access

Continue reading with a
two-week free trial.